Literature DB >> 12928128

[Mode of action of botulinum neurotoxin: pathological, cellular and molecular aspect].

B Poulain1, Y Humeau.   

Abstract

Several bacteria of the Clostridium genus (C. botulinum) produce 150 kDa di-chainal protein toxins referred as botulinum neurotoxins or BoNTs. They associate with non-toxic companion proteins and form a complex termed botulinum toxin or BoTx. The latter is used in clinic for therapeutic purpose. BoNTs affect cholinergic nerve terminals in periphery where they block acetylcholine release, thereby causing dysautonomia and motorparalysis (i.e. botulism). The cellular action of BoNTs can be depicted according to a three steps model: binding, internalisation and intraneuronal action. The toxins heavy chain mediates binding to specific receptors followed by endocytotic internalisation of BoNT/receptor complex. BoNT receptors may comprise gangliosides and synaptic vesicle-associated proteins as synaptotagmins. Vesicle recycling induces BoNT internalisation. Upon acidification of vesicles, the light chain of the neurotoxin is translocated into the cytosol. Here, this zinc-endopeptidase cleaves one or two among three synaptic proteins (VAMP-synaptobrevin, SNAP25, and syntaxin). As the three protein targets of BoNT play major role in fusion of synaptic vesicles at the release sites, their cleavage is followed by blockage of neurotransmitter exocytosis. The duration of the paralytic effect of the BoNTs is determined by 1) the turnover of their protein target; 2) the time-life of the toxin light chain in the cytosol, and 3) the sprouting of new nerve-endings that are retracted when the poisoned nerve terminal had recovered its full functionality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928128     DOI: 10.1016/s0168-6054(03)00114-4

Source DB:  PubMed          Journal:  Ann Readapt Med Phys        ISSN: 0168-6054


  6 in total

1.  Engineering botulinum neurotoxin to extend therapeutic intervention.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-01       Impact factor: 11.205

2.  Persistent neurogenic bladder dysfunction due to infantile botulism.

Authors:  Anders Breinbjerg; Søren Rittig; Konstantinos Kamperis
Journal:  BMJ Case Rep       Date:  2014-01-13

3.  Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A.

Authors:  Julie Prigent; Christelle Mazuet; Didier Boquet; Patricia Lamourette; Hervé Volland; Michel R Popoff; Christophe Créminon; Stéphanie Simon
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

Review 4.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

5.  Effects of quadriceps muscle fatigue on stiff-knee gait in patients with hemiparesis.

Authors:  Julien Boudarham; Nicolas Roche; Didier Pradon; Eric Delouf; Djamel Bensmail; Raphael Zory
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

6.  Optogenetically controlled human functional motor endplate for testing botulinum neurotoxins.

Authors:  Juliette Duchesne de Lamotte; Jérôme Polentes; Florine Roussange; Léa Lesueur; Pauline Feurgard; Anselme Perrier; Camille Nicoleau; Cécile Martinat
Journal:  Stem Cell Res Ther       Date:  2021-12-05       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.